Darktrace

Darktrace is valued at $1.7B.

Investor information for Darktrace is not publicly available at this time.

No public funding round data is currently available for Darktrace.

Darktrace has approximately 1000-5000 employees.

Darktrace is an AI cybersecurity company that applies unsupervised machine learning to detect and respond to cyber threats inside enterprise networks, email systems, cloud environments, and operational technology. The Cambridge-based company pioneered the concept of the enterprise immune system, training AI models on each organisation normal network behaviour to identify anomalies that indicate intrusion, insider threat, or ransomware activity in real time without requiring predefined threat signatures.\n\nThe company went public on the London Stock Exchange in 2021, raising approximately $230 million in its IPO after backing from Invoke Capital, Vitruvian Partners, and KKR. Darktrace reports over 9,000 enterprise customers across more than 100 countries, including significant deployments in financial services, healthcare, and critical infrastructure. The company has expanded from network detection to autonomous response capabilities through its Antigena product, which can quarantine infected systems and neutralise threats without human intervention.\n\nDarktrace competes in the AI-native cybersecurity market against CrowdStrike, SentinelOne, and Microsoft Defender, as well as against SIEM vendors including Splunk and IBM QRadar. The company valuation and public market performance have been volatile, reflecting broader uncertainty around AI cybersecurity spending cycles and questions about autonomous response effectiveness in complex enterprise environments. Its AI self-learning approach, applied consistently across network, email, cloud, and OT security, remains a distinctive architecture compared to detection-rule-based competitors, and the Poppy Gustafsson leadership profile has made Darktrace a flagship case study for UK technology entrepreneurship.